More bad Brillinta news.

Quote

Anonymous

Guest
Study finds patients often stop using new AstraZeneca heart drug

Reuters - UK Focus – 4 hours ago
Email
ShareTweet
Print
Companies:
AstraZeneca PLCSanofi
RELATED QUOTES
Symbol Price Change
AZN 49.21

GCVRZ 1.86
AMSTERDAM, Sept 3 (Reuters) - Use of AstraZeneca (NYSE: AZN - news) 's new heart drug Brilinta is frequently discontinued in a real world setting, according to a small clinical study presented on Tuesday.
The finding may raise questions about the uptake of Brilinta, a key new product for AstraZeneca as it seeks to replace older drugs losing patent protection, although the drugmaker played down the significance of the research.
The 367-patient study presented as a poster at the European Society of Cardiology showed that around 14 percent of patients prematurely stopped taking the blood-thinning drug or switched to an alternative, most frequently due to experiencing breathlessness.
Brilinta is used to prevent recurrent heart attacks or strokes.
Dr. Thomas Bergmeijer of the St. Antonius Hospital Nieuwegein in the Netherlands and colleagues, who carried out the study between December 2011 and December 2012, said the discontinuation rate due to dyspnea, or shortness of breath, was higher than expected.
An AstraZeneca spokeswoman said that while the discontinuation rate was higher than in the original 18,000-patient study, dubbed PLATO, that led to Brilinta's approval, the rate was similar to that seen with Sanofi (NasdaqGM: GCVRZ - news) 's rival product Plavix in the real world.
 




Anonymous said:
Study finds patients often stop using new AstraZeneca heart drug

Reuters - UK Focus – 4 hours ago
Email
ShareTweet
Print
Companies:
AstraZeneca PLCSanofi
RELATED QUOTES
Symbol Price Change
AZN 49.21

GCVRZ 1.86
AMSTERDAM, Sept 3 (Reuters) - Use of AstraZeneca (NYSE: AZN - news) 's new heart drug Brilinta is frequently discontinued in a real world setting, according to a small clinical study presented on Tuesday.
The finding may raise questions about the uptake of Brilinta, a key new product for AstraZeneca as it seeks to replace older drugs losing patent protection, although the drugmaker played down the significance of the research.
The 367-patient study presented as a poster at the European Society of Cardiology showed that around 14 percent of patients prematurely stopped taking the blood-thinning drug or switched to an alternative, most frequently due to experiencing breathlessness.
Brilinta is used to prevent recurrent heart attacks or strokes.
Dr. Thomas Bergmeijer of the St. Antonius Hospital Nieuwegein in the Netherlands and colleagues, who carried out the study between December 2011 and December 2012, said the discontinuation rate due to dyspnea, or shortness of breath, was higher than expected.
An AstraZeneca spokeswoman said that while the discontinuation rate was higher than in the original 18,000-patient study, dubbed PLATO, that led to Brilinta's approval, the rate was similar to that seen with Sanofi (NasdaqGM: GCVRZ - news) 's rival product Plavix in the real world.
Click to expand...

Nothing to see here. Move along now! Just because the patients on The B can't breathe, is of little concern. Our messaging will get us through! Just ask the patient this question, "would you prefer breathing, or would you rather stroke out?" That will get em'!
 




Isn't that why we contracted a bunch of nurses to help us lie to our customers. Don't worry shortness of breath is nothing to be concerned about. Yeah unless you have a rope around you neck!
 




Stop blowing it out of proportion. Adherence is a problem for all drugs, and a 14% drop of rate is incredibly good. AZ would kill for that kind of adherence across the portfolio.
 
























We'll fill the airwaves with ads and blow this thing out, so you guys suck it up. Take a deep breath and smell the coffee. All of the hype about shortness of breath is overblown. The blowhard competition is behind this. What we all need is a breath is fresh air.
 








Anonymous said:
Stop blowing it out of proportion. Adherence is a problem for all drugs, and a 14% drop of rate is incredibly good. AZ would kill for that kind of adherence across the portfolio.[/QUOth

The point is that it is a much bigger deal. Obviously, it does not resolve for most patients as trial and PI sufgesrs. Feeling like you can't breathe is scary. I have been able to get some docs back on board but in my are of the country.... i can't think of one patient where the dypsnea went away after 1-2 weeks. At fhe risk of being callous this side effect makes the drug hard to sell. We have on several stemi protocols but the md discharge patients on plavix because at least 25 % of B patients come back complaing of Sob
K
Click to expand...
 








The new data is the same as what we tell our doctors: 14 percent. It is hard to say if patients are really willing to give it time to resolve or not, or just how long that might be. I do think when it happens, it is a problem. But it is not any more harmful than an ACE cough. If the pt decides they cannot tolerate it for a year, so be it. They can go back to P and their risk of CV death or an MI is greater. Whatever.
 




Who gives a rat's ass about patients anyway! It's all about sales baby, sales! you think I care if they are having a little trouble breathing?? It's good for them! It puts the fear of God into them!! GO B GO!
 




















Anonymous said:
The new data is the same as what we tell our doctors: 14 percent. It is hard to say if patients are really willing to give it time to resolve or not, or just how long that might be. I do think when it happens, it is a problem. But it is not any more harmful than an ACE cough. If the pt decides they cannot tolerate it for a year, so be it. They can go back to P and their risk of CV death or an MI is greater. Whatever.
Click to expand...

The new data is not the same, at first I thought it was. 14 is the percentage of Plato patients that experienced dyspnea but only 0.9 % discontinued it. The abstract said that 14% is the discontinuation rate, that is 14x increase of discontinuation of B in the real world setting.

The problem is that in my rural territory patients ( and rightfully so ) call 911 if they are Short of breath. My experience is that the dyspnea does not always start while the patient is still in the hospital but when they get home. Despite education any EMT/ER doc will tell you that if you are 5 days post stemi and are experiencing shortness of breath it is an emergency.

I have a great nurse educater if the dyspnea happens in the hosptital no big deal that staff rules out other causes, discharges the patient on B...... but shit load of my cases don't happen that way
 




Top Bottom
Back
Quote